How can I test for infectious mononucleosis (caused by Epstein‑Barr virus)?

Testing for Infectious Mononucleosis

Initial Diagnostic Approach

Begin with a rapid heterophile antibody test (Monospot) combined with a complete blood count with differential as your first-line testing strategy for suspected infectious mononucleosis in adolescents and adults. 1, 2

First-Line Testing

• Order a rapid heterophile antibody test as the initial screening test in adolescents and adults with suspected infectious mononucleosis 1
• Obtain a complete blood count with differential to look for:
  • Elevated white blood cell count with at least 50% lymphocytes 3
  • More than 10% atypical lymphocytes of the total lymphocyte count 3, 4
  • Lymphocyte count greater than 4,000/mm³ (IM is unlikely if below this threshold) 5

Timing Considerations for Heterophile Testing

• The heterophile antibody becomes detectable between days 6-10 after symptom onset and peaks during weeks 2-3 of illness 1
• The test has a 25% false-negative rate in the first week of illness 5
• If the initial Monospot is negative but clinical suspicion remains high, repeat the test on a serum specimen obtained 7-10 days later 6

When Heterophile Testing is Negative

If the heterophile test is negative and clinical suspicion remains high, proceed immediately to EBV-specific antibody testing including VCA IgM, VCA IgG, and EBNA antibodies. 1, 2

EBV-Specific Antibody Panel

• VCA IgM indicates acute or recent infection 1
• VCA IgG develops rapidly in acute infection and persists for life 1
• EBNA antibodies are critical for timing the infection; they develop 1-2 months after primary infection and persist for life 1

Interpreting EBV Antibody Results

• VCA IgM positive + EBNA antibodies absent = recent primary EBV infection (less than 6 weeks) 1, 2
• EBNA antibodies present + VCA IgM absent = past infection (more than 6 weeks ago), making EBV unlikely as the cause of current symptoms 1, 2
• Over 90% of normal adults have IgG antibodies to VCA and EBNA from past infection 1

Special Population Testing

Children Under 10 Years

• False-negative heterophile results occur in approximately 10% of patients and are especially common in children younger than 10 years 2
• Proceed directly to EBV-specific antibody testing in this age group rather than relying on heterophile tests 2, 6

Immunocompromised Patients

For transplant recipients, HIV-infected individuals, and those with congenital immunodeficiencies, order quantitative EBV viral load testing by nucleic acid amplification test (NAAT) in peripheral blood rather than relying solely on serology. 1, 6

• EBV DNA levels > 10^2.5 copies/mg DNA in peripheral blood mononuclear cells indicate active infection 1, 6
• Post-transplant patients require EBV DNA surveillance due to high risk of lymphoproliferative disease 1

Specimen Collection

• Collect serum specimens as soon as possible after symptom onset for serologic testing 1
• For EBV DNA detection, use whole blood, peripheral blood lymphocytes, or plasma in EDTA tube at room temperature, transported within 2 hours 6

Chronic Active EBV Infection (CAEBV)

If patients have persistent or recurrent symptoms, consider CAEBV testing:

• Markedly elevated VCA IgG titers (≥1:640) combined with elevated EA IgG (≥1:160) suggest CAEBV 1, 6
• Positive IgA antibodies to VCA and/or EA are often demonstrated in CAEBV 1, 6
• EBV DNA >10^2.5 copies/mg DNA in peripheral blood mononuclear cells indicates active infection 6

Critical Pitfalls to Avoid

• Do NOT order EBV testing from throat swabs—EBV can persist in throat secretions for weeks to months after infection and does not confirm acute infection 1, 6
• Do NOT interpret the presence of EBNA antibodies as indicating acute infection; these develop 1-2 months post-infection and indicate past exposure 1
• Do NOT rely solely on heterophile testing in the first week of illness—wait until days 6-10 or proceed directly to EBV-specific antibodies 1, 5
• Remember that 5-10% of infected patients may not develop EBNA antibodies despite infection, particularly immunocompromised individuals 1, 2
• Consider alternative diagnoses including CMV, adenovirus, HIV, and Toxoplasma gondii when evaluating mononucleosis-like illness 2